

Mateus Crespo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9117321/publications.pdf>

Version: 2024-02-01

40
papers

3,194
citations

201674

27
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

5309
citing authors

#	ARTICLE	IF	CITATIONS
1	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.9	23
2	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 659-667.	5.4	8
3	Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3104-3115.	7.0	12
4	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 566-574.	7.0	50
5	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	9.4	124
6	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation â€” a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100309.	1.7	2
7	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
8	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
9	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT48.	1.5	7
10	Preliminary evidence of antitumour activity of lpatasertib (lpat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787). <i>Neuro-Oncology</i> , 2021, 23, iv10-iv10.	1.2	0
11	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.9	25
12	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	10.7	450
13	Elucidating Durable Responses to Immune Checkpoint Inhibition. <i>European Urology</i> , 2020, 78, 639-641.	1.9	3
14	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
15	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	7.0	21
16	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	1.9	62
17	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 687-697.	7.0	43
18	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 796-808.	6.4	103

#	ARTICLE	IF	CITATIONS
19	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	7.0	111
20	EpCAM ^{high} and EpCAM ^{low} circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , 2018, 9, 35705-35716.	1.8	70
21	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 4441-4453.	8.2	155
22	Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles. <i>Cancers</i> , 2018, 10, 416.	3.7	30
23	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , 2018, 559, 363-369.	27.8	258
24	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , 2018, 24, 5585-5593.	7.0	113
25	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	5.1	68
26	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018, 24, 5635-5644.	7.0	88
27	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 19283-19293.	1.8	54
28	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	9.4	341
29	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3101-3112.	0.9	68
30	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017, 23, 6070-6077.	7.0	30
31	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017, 120, E30-E44.	2.5	54
32	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 341-358.	8.2	83
33	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 485-493.	1.9	30
34	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.9	79
35	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 985-992.	1.9	119
36	Sarcomatoid carcinoma of the prostate: <i>in situ</i> ERG fluorescence <i>in situ</i> hybridization confirms epithelial origin. <i>Histopathology</i> , 2015, 66, 898-901.	2.9	26

#	ARTICLE	IF	CITATIONS
37	Visceral Disease in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 270-273.	1.9	172
38	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju033.	6.3	59
39	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1609-1617.	4.1	82
40	Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negative Letter: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 3048-3049.	7.0	18